Skeletal muscle energetics explain the sex disparity in mobility impairment in the Study of Muscle, Mobility and Aging (SOMMA) - Kramer, Philip A.; Coen, Paul M.; Cawthon, Peggy M.; Distefano, Giovanna; Cummings, Steven R.; Goodpaster, Bret H.; Hepple, Russell T.; Kritchevsky, Stephen B.; Shankland, Eric G.; Marcinek, David J.; Toledo, Frederico G. S.; Duchowny, Kate A.; et al. (medRxiv, 2023)
The age-related decline in muscle mitochondrial energetics contributes to the loss of mobility in older adults. Women experience a higher prevalence of mobility impairment compared to men, but it is unknown whether sex-specific differences in muscle energetics underlie this disparity. In the Study of Muscle, Mobility and Aging (SOMMA), muscle energetics were characterized using in vivo phosphorus-31 magnetic resonance spectroscopy and high-resolution respirometry of vastus lateralis biopsies in 773 participants (56.4% women, age 70-94 years). A Short Physical Performance Battery score <= 8 was used to define lower-extremity mobility impairment. Muscle mitochondrial energetics were lower in women compared to men (e.g. Maximal Complex I&II OXPHOS: Women=55.06 +/- 15.95; Men=65.80 +/- 19.74; p<0.001) and in individuals with mobility impairment compared to those without (e.g., Maximal Complex I&II OXPHOS in women: SPPB>=9=56.59 +/- 16.22; SPPB<=8=47.37 +/- 11.85; p<0.001). Muscle energetics were negatively associated with age only in men (e.g., Maximal ETS capacity: R=-0.15, p=0.02; age/sex interaction, p=0.04), resulting in muscle energetics measures that were significantly lower in women than men in the 70-79 age group but not the 80+ age group. Similarly, the odds of mobility impairment were greater in women than men only in the 70-79 age group (70-79 age group, ORage-adjusted=1.78, 95% CI=1.03, 3.08, p=0.038; 80+ age group, ORage-adjusted=1.05, 95% CI=0.52, 2.15, p=0.89). Accounting for muscle energetics attenuated up to 75% of the greater odds of mobility impairment in women. Women had lower muscle mitochondrial energetics compared to men, which largely explain their greater odds of lower-extremity mobility impairment.Competing Interest StatementS Cummings and P Cawthon are consultants to Bioage Labs. All other authors report no conflict of interest.Funding StatementThe Study of Muscle, Mobility and Aging is supported by funding from the National Institute on Aging (NIA) R01AG059416. A. Molina’s efforts was supported by the following grants from the NIA: R01 AG054523, R01AG061805, U01 AG060897, and R56 AG057864. G Distefano is supported by the American Diabetes Association (1-19- PDF-006). K Duchowny is supported by K99AG066846. Study infrastructure support was funded in part by NIA Claude D. Pepper Older American Independence Centers at University of Pittsburgh (P30AG024827), Wake Forest University School of Medicine (P30AG021332), the Clinical and Translational Science Institutes which is funded by the National Center for Advancing Translational Science at Wake Forest University School of Medicine (UL1TR001420).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Study of Muscle, Mobility and Aging (SOMMA; https://www.sommastudy.com/) recruited and consented 879 participants aged 70 years and older at The University of Pittsburgh and Wake Forest University School of Medicine from April 2019 to December 2021 as approved by WIRB-Copernicus Group (WCG IRB)(20180764).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.sommastudy.com/